OCH

OCH (also known as OCH-NCNP1) is an experimental oral glycolipid molecule developed by the National Center of Neurology and Psychiatry in Japan. It is designed to activate anti-inflammatory responses, particularly from natural killer T-cells (NKT cells), which are immune cells capable of producing both pro- and anti-inflammatory molecules. By promoting the anti-inflammatory function of NKT cells, OCH aims to reduce inflammation associated with multiple sclerosis (MS). Early data suggest it is generally well tolerated and effectively activates anti-inflammatory immune cells. It is currently being investigated for the treatment of relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS).

Other names

(2S, 3S, 4R)-1-O-(α-d-galactosyl)-2-tetracosanoylamino-1,3,4-nonaetriol